Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Status epilepticus Stories

2013-11-01 08:27:55

Findings Presented at 42nd Annual Child Neurology Society Meeting MAPLE GROVE, Minn., Nov. 1, 2013 /PRNewswire/ -- A new systematic review found that when compared with intravenous or rectally administered diazepam, intranasal midazolam was equally effective and demonstrated comparable safety for the treatment of acute seizure emergencies in pediatric patients. Findings from the systematic review were presented at the 42(nd) Annual Child Neurology Society meeting in Austin, Texas, October 30...

2013-06-24 08:28:48

Extension Study Offers Patients Experiencing Seizure Clusters Continued Access to USL261 MAPLE GROVE, Minn., June 24, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., (Upsher-Smith) today announced that it is enrolling patients in its open-label safety extension study to ARTEMIS1 (Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray), a global Phase III clinical trial for USL261, a novel, investigational formulation of the benzodiazepine midazolam. USL261 is...

2013-03-25 04:22:08

UCLA Case Study Results To Be Presented At Major International Status Epilepticus Conference In Salzburg, Austria LOS ANGELES, March 25, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch(TM) eTNS(TM) System for the adjunctive treatment of epilepsy and depression, at the 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures to be held in Salzburg, Austria...

2013-03-19 12:27:26

USL261 Demonstrated Improved Bioavailability of Midazolam, Similar Pharmacodynamic Effects, and Comparable Tolerability as Compared with Injectable Midazolam Administered Intranasally in Healthy Volunteers MAPLE GROVE, Minn., March 19, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., (Upsher-Smith) today announced that Phase I data for USL261 (intranasal midazolam) in healthy volunteers were presented at the Annual American Academy of Neurology (AAN) Meeting in San Diego, CA....

2012-11-26 08:25:19

MAPLE GROVE, Minn., Nov. 26, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system, is proud to sponsor emerging data on USL261, its novel formulation of intranasal midazolam, at the 66(th) Annual Meeting of the American Epilepsy Society (AES) in San Diego, CA, November 30 - December 4, 2012. "Upsher-Smith is committed to working toward...

2012-11-08 16:15:22

NIH-funded study is following nearly 200 children Seizures during childhood fever are usually benign, but when prolonged, they can foreshadow an increased risk of epilepsy later in life. Now a study funded by the National Institutes of Health suggests that brain imaging and recordings of brain activity could help identify the children at highest risk. The study reveals that within days of a prolonged fever-related seizure, some children have signs of acute brain injury, abnormal brain...

2012-06-21 02:26:50

Announce Fall Grant Application Cycle is Now Open WASHINGTON, June 21, 2012 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of their New Therapy Grants Program, a unique joint venture of the two non-profit epilepsy organizations to advance clinical development and commercialization of promising epilepsy therapies. The grant awards will support the development of four important new technologies:...

2012-06-14 11:11:40

One-third of febrile seizures associated with roseola virus New research shows that human herpesviruses (HHV)-6B and HHV-7, commonly know as roseola virus), account for one third of febrile status epilepticus (FSE) cases. Results of the FEBSTAT prospective study now available in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy (ILAE), suggest that HHV-6B may be involved in the development of epilepsy and further research is urgently...

2012-04-26 06:25:31

MAPLE GROVE, Minn., April 26, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the launch of http://www.seizureclusterstudy.com, an informational website for individuals diagnosed with partial or generalized epilepsy who experience seizure clusters and are interested in participating in an ongoing Phase III clinical trial. The study, ARTEMIS1 (Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray) is designed to evaluate the efficacy and safety of USL261, an...

2012-02-16 14:57:15

Drug delivery directly into muscle using an autoinjector is faster and may be more effective in stopping prolonged seizures, according to a study sponsored by the National Institutes of Health and conducted by a Wayne State University School of Medicine researcher. The trial compared the effectiveness of two Federal Drug Administration-approved anti-seizure medications and how they are administered to patients suffering prolonged seizures before they arrive at hospitals. The Rapid...